TWI426901B - 癌的預防或治療藥物 - Google Patents

癌的預防或治療藥物 Download PDF

Info

Publication number
TWI426901B
TWI426901B TW097141333A TW97141333A TWI426901B TW I426901 B TWI426901 B TW I426901B TW 097141333 A TW097141333 A TW 097141333A TW 97141333 A TW97141333 A TW 97141333A TW I426901 B TWI426901 B TW I426901B
Authority
TW
Taiwan
Prior art keywords
group
drug
pyrrolo
dihydro
compound
Prior art date
Application number
TW097141333A
Other languages
English (en)
Chinese (zh)
Other versions
TW200927097A (en
Inventor
Masuo Yamaoka
Takahito Hara
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI426901(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of TW200927097A publication Critical patent/TW200927097A/zh
Application granted granted Critical
Publication of TWI426901B publication Critical patent/TWI426901B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
TW097141333A 2007-10-29 2008-10-28 癌的預防或治療藥物 TWI426901B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007280813 2007-10-29

Publications (2)

Publication Number Publication Date
TW200927097A TW200927097A (en) 2009-07-01
TWI426901B true TWI426901B (zh) 2014-02-21

Family

ID=40591618

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097141333A TWI426901B (zh) 2007-10-29 2008-10-28 癌的預防或治療藥物

Country Status (17)

Country Link
US (2) US20100261689A1 (es)
EP (1) EP2205239A2 (es)
JP (1) JP5430576B2 (es)
KR (1) KR20100088144A (es)
CN (1) CN101909622B (es)
AR (1) AR069079A1 (es)
AU (1) AU2008319767B8 (es)
CA (1) CA2703780A1 (es)
CL (1) CL2008003198A1 (es)
IL (1) IL205368A (es)
MX (1) MX2010004405A (es)
NZ (1) NZ585473A (es)
PE (2) PE20130603A1 (es)
RU (1) RU2481107C2 (es)
SG (1) SG185930A1 (es)
TW (1) TWI426901B (es)
WO (1) WO2009057795A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33740A (es) * 2010-11-18 2012-05-31 Takeda Pharmaceutical Método para tratar el cáncer de mama y cáncer de ovarios
TW201309291A (zh) * 2011-05-17 2013-03-01 Takeda Pharmaceutical 治療癌症之醫藥組合物及方法
US10201549B2 (en) 2013-06-14 2019-02-12 Professional Compounding Centers Of America (Pcca) Testosterone combined with anastrozole injection solutions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040484A2 (en) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Novel imidazole derivatives, production method thereof and use thereof
WO2006093353A1 (ja) * 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited 放出制御組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2244823A1 (en) * 1996-02-14 1997-08-21 Hoechst Marion Roussel, Inc. 17-beta-cyclopropyl(amino/oxy) 4-aza steroids as active inhibitors of testosterone 5-alpha-reductase and c17-20-lyase
PE20010781A1 (es) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
CA2700690C (en) * 2002-01-10 2013-09-10 Takeda Pharmaceutical Company Limited Process for producing reformatsky reagent in stable form
EP1615944A4 (en) * 2003-04-01 2010-08-11 Harbor Biosciences Inc ANTI-ORANGE PROBLEMS WITH MARGINAL AGONIST EFFECT AND METHOD OF USE
CA2521221A1 (en) * 2003-04-02 2004-10-14 Genix Therapeutics, Inc. Method for the treatment of prostate cancer
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
EP1861109A2 (en) * 2005-03-09 2007-12-05 Cardax Pharmaceuticals, Inc. Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
PL2478907T3 (pl) * 2006-08-25 2021-10-25 Janssen Oncology, Inc. Kompozycje do leczenia nowotworu
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040484A2 (en) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Novel imidazole derivatives, production method thereof and use thereof
WO2006093353A1 (ja) * 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited 放出制御組成物

Also Published As

Publication number Publication date
IL205368A0 (en) 2010-12-30
PE20130603A1 (es) 2013-05-30
AU2008319767A1 (en) 2009-05-07
MX2010004405A (es) 2010-05-03
CN101909622B (zh) 2013-06-19
SG185930A1 (en) 2012-12-28
JP2011502114A (ja) 2011-01-20
CA2703780A1 (en) 2009-05-07
AR069079A1 (es) 2009-12-30
IL205368A (en) 2014-08-31
WO2009057795A2 (en) 2009-05-07
AU2008319767A8 (en) 2014-01-09
CL2008003198A1 (es) 2009-12-18
NZ585473A (en) 2012-03-30
AU2008319767B2 (en) 2013-12-19
CN101909622A (zh) 2010-12-08
EP2205239A2 (en) 2010-07-14
US20140256693A1 (en) 2014-09-11
PE20090931A1 (es) 2009-08-03
JP5430576B2 (ja) 2014-03-05
RU2010121765A (ru) 2011-12-10
WO2009057795A8 (en) 2010-05-14
AU2008319767A2 (en) 2010-06-17
WO2009057795A3 (en) 2009-07-09
US20100261689A1 (en) 2010-10-14
TW200927097A (en) 2009-07-01
RU2481107C2 (ru) 2013-05-10
KR20100088144A (ko) 2010-08-06
AU2008319767B8 (en) 2014-01-09

Similar Documents

Publication Publication Date Title
EP3864003B1 (en) Prodrug modulators of the integrated stress pathway
JP6754071B2 (ja) メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
JP2021501142A (ja) キナーゼを調節する化合物の製剤
CA3177990A1 (en) Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
AU2014254050B2 (en) Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
US20200237711A1 (en) Compositions for Treating and/or Preventing Cancer
TW201245204A (en) Imidazopyridazines
JP2008501708A (ja) がんの治療方法
TWI426901B (zh) 癌的預防或治療藥物
JP2003201282A (ja) 新規イミダゾール誘導体、その製造法および用途
EP2359825A2 (en) Combination drug
IL258651A (en) Treatment of symptoms associated with androgen deficiency therapy
US20220288019A1 (en) Methods of treating cancer using a combination of SERD Dosing Regimens
JP2023501584A (ja) Ｃ－ｃケモカイン受容体４型アンタゴニストの結晶形態、およびその使用
WO2009110415A1 (ja) 併用剤
JP2023088898A (ja) 高リスク転移性ホルモン感受性前立腺がんの治療用の組み合わせ
WO2023152611A1 (en) Apalutamide and relugolix for the treatment of prostate cancer
WO2009110416A1 (ja) 併用剤
JP2024539485A (ja) キナーゼ阻害剤の新規用途

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees